HeraMEDSTU:1I4 +5.00% EBITDA Margin % is -1,217.24% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, HeraMED ranks worse than 94.73% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HeraMED's EBITDA for the
six
months ended in Dec. 2025 was €-1.06 Mil. HeraMED's Revenue for the
six
months ended in Dec. 2025 was €0.09 Mil. Therefore, HeraMED's EBITDA margin for the quarter that ended in Dec. 2025 was -1,217.24%.
HeraMED (STU:1I4) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HeraMED EBITDA Margin % Related Terms
HeraMED EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HeraMED's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1I4 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, HeraMED's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HeraMED's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (STU:1I4) has a EBITDA Margin % of -1,217.24% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HeraMED and its competitors. According to the industry distribution chart, HeraMED ranks #773 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 94.7%.
Is HeraMED's EBITDA Margin % too high?
HeraMED's current EBITDA Margin % is -1,217.24%. Based on the distribution chart, HeraMED ranks #773 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does HeraMED's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #773 out of 816 companies for EBITDA Margin %. This places HeraMED in the lower half of its industry. The industry median EBITDA Margin % is 7.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current EBITDA Margin % is -1,217.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (STU:1I4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 110% above its estimated fair value. The current EBITDA Margin % is -1,217.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HeraMED (STU:1I4), the current EBITDA Margin % is -1,217.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1I4 has been successfully added to your 